All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
G250 refers to a monoclonal antibody (mAb) that was raised more than 10 years ago by immunization of mice with human renal cell carcinoma(RCC) homogenates. The RCC-associated transmembrane protein designated G250 has since been proven to be identical to tumor-associated protein MN or CA IX. The normal function of CA IX is to catalyze the reversible conversion of carbon dioxide and water to carbonic acid, playing a role in the intra- and extracellular pH regulation of cells. It has been implicated as an intrinsic marker of hypoxia and as a prognostic marker for several types of human tumors. CA IX has also been shown to be a useful prognostic biomarker for RCC.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC371 | Anti-CA9 h(CD28-41BB-CD3ζ, iRGD) Armoured CAR, pCDCAR1 | Human | Human | iRGD-scFv-CD28-41BB-CD3ζ | Lentiviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION